Serum levels of angiogenic factors in early breast cancer remain close to normal

Breast. 2009 Feb;18(1):26-9. doi: 10.1016/j.breast.2008.09.004. Epub 2008 Nov 8.


The study which we performed was to determine serum concentrations of angiogenic factors including VEGF, angiogenin and TGF-beta 1 in early stage breast cancer patients. These parameters were measured by ELISA in sera of 90 patients with breast cancer and 75 healthy controls. The mean serum VEGF concentration in patients compared to controls was not significantly different (0.33ng/mL vs 0.43ng/mL, respectively; p=0.156). Likewise, the insignificant change in mean values in patients vs controls was also observed for serum TGF-beta 1 (0.19ng/mL vs 0.19ng/mL, respectively; p=0.215) and serum angiogenin (243.24ng/mL vs 244.5ng/mL, respectively; p=0.976). Statistically significant correlation was found only between the tests, such as VEGF and angiogenin in patients who were included in the study (p<0.001). In conclusion, we couldn't find any diagnostic value between the early stage breast cancer and the three angiogenic parameters.

MeSH terms

  • Adult
  • Aged
  • Biomarkers, Tumor / blood
  • Breast Neoplasms / blood*
  • Breast Neoplasms / diagnosis
  • Female
  • Humans
  • Middle Aged
  • ROC Curve
  • Ribonuclease, Pancreatic / blood*
  • Sensitivity and Specificity
  • Transforming Growth Factor beta1 / blood*
  • Vascular Endothelial Growth Factor A / blood*


  • Biomarkers, Tumor
  • Transforming Growth Factor beta1
  • Vascular Endothelial Growth Factor A
  • angiogenin
  • Ribonuclease, Pancreatic